Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials

Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the clinical deterioration of Alzheimer’s disease (AD). Recently, targeted-Aβ plaque reduction immunotherapies have been explored for their efficacy and safety as AD treatment. This systematic review critically revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashad, Areeba, Rasool, Atta, Shaheryar, Muhammad, Sarfraz, Azza, Sarfraz, Zouina, Robles-Velasco, Karla, Cherrez-Ojeda, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818878/
https://www.ncbi.nlm.nih.gov/pubmed/36611492
http://dx.doi.org/10.3390/healthcare11010032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818878/
https://www.ncbi.nlm.nih.gov/pubmed/36611492
http://dx.doi.org/10.3390/healthcare11010032

Ejemplares similares